We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent Technologies (A) to Post Q1 Earnings: What's in Store?
Read MoreHide Full Article
Agilent Technologies (A - Free Report) is set to report its first-quarter fiscal 2023 results on Feb 28.
For the fiscal first quarter, A expects revenues of $1.68-$1.70 billion, suggesting growth between 6.8% and 8% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.69 billion, implying growth of 1.1% from the year-ago fiscal quarter’s reported figure.
A’s Non-GAAP earnings are expected to be $1.29-1.31 per share. The Zacks Consensus Estimate for earnings is pegged at $1.31 per share, indicating growth of 8.3% from the year-ago fiscal quarter’s reported figure.
Agilent’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average being 6.74%.
Key Factors to Note
Agilent’s performance in the fiscal first quarter is likely to have benefited from solid momentum in the pharma and applied markets.
Further, the company’s growing momentum across chemical & advanced materials, food, and environmental & forensics markets is likely to have remained a positive in the to-be-reported quarter.
Additionally, A’s strength in the Life Sciences & Applied Markets Group (LSAG) segment, owing to growth in Liquid Chromatography and Mass Spectrometry instruments, is expected to have contributed well in the quarter under review.
The Zacks Consensus Estimate for LSAG is pegged at $988 million, implying growth of 1.2% from the year-ago fiscal quarter’s reported figure.
Moreover, during the fiscal first quarter, Agilent’s Cross Lab Group (ACG) segment is likely to have benefited from an increase in the service agreement connect rate.
The Zacks Consensus Estimate for ACG is pegged at $363 million, implying growth of 1.1% from the year-ago fiscal quarter’s reported figure.
Agilent’s Strength in NASD and Genomics portfolio is likely to have contributed well to the Diagnostics and Genomics Group (DGG) segment in its first quarter fiscal results.
The Zacks Consensus Estimate for DGG is pegged at $343 million, implying growth of 1.2% from the year-ago fiscal quarter’s reported figure.
Furthermore, strength in the Americas region and growth in the European and China businesses are expected to have remained tailwinds in the quarter under discussion.
However, uncertainties related to the coronavirus pandemic are expected to get reflected in the upcoming quarterly results.
Further, mounting expenses and macroeconomic headwinds are likely to have remained a concern in the quarter under review.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for A this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter
Agilent has an Earnings ESP of 0.00% and a Zacks Rank #2 at present.
Stocks to Consider
Here are some stocks that you may consider, as our model shows that they have the right combination of elements to beat on earnings this season.
CrowdStrike is scheduled to release its fourth-quarter fiscal 2023 results on Mar 7. The Zacks Consensus Estimate for CRWD’s earnings is pegged at 43 cents per share, suggesting an increase of 43.3% from the prior-year quarter’s reported figure.
Axonics (AXNX - Free Report) has an Earnings ESP of +31.03% and a Zacks Rank #3 at present.
Axonics is set to report its fourth-quarter 2022 results on Mar 1. The Zacks Consensus Estimate for AXNX’s loss is pegged at 23 cents per share, narrower than the loss of 34 cents reported in the year-ago quarter.
Broadcom (AVGO - Free Report) ESP of +1.36% and a Zacks Rank #3 at present.
Broadcom is scheduled to release its first-quarter fiscal 2023 results on Mar 2. The Zacks Consensus Estimate for AVGO’s earnings is pegged at $10.16 per share, suggesting an increase of 21.1% from the prior-year period’s reported figure.
Image: Bigstock
Agilent Technologies (A) to Post Q1 Earnings: What's in Store?
Agilent Technologies (A - Free Report) is set to report its first-quarter fiscal 2023 results on Feb 28.
For the fiscal first quarter, A expects revenues of $1.68-$1.70 billion, suggesting growth between 6.8% and 8% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.69 billion, implying growth of 1.1% from the year-ago fiscal quarter’s reported figure.
A’s Non-GAAP earnings are expected to be $1.29-1.31 per share. The Zacks Consensus Estimate for earnings is pegged at $1.31 per share, indicating growth of 8.3% from the year-ago fiscal quarter’s reported figure.
Agilent’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average being 6.74%.
Key Factors to Note
Agilent’s performance in the fiscal first quarter is likely to have benefited from solid momentum in the pharma and applied markets.
Further, the company’s growing momentum across chemical & advanced materials, food, and environmental & forensics markets is likely to have remained a positive in the to-be-reported quarter.
Additionally, A’s strength in the Life Sciences & Applied Markets Group (LSAG) segment, owing to growth in Liquid Chromatography and Mass Spectrometry instruments, is expected to have contributed well in the quarter under review.
The Zacks Consensus Estimate for LSAG is pegged at $988 million, implying growth of 1.2% from the year-ago fiscal quarter’s reported figure.
Moreover, during the fiscal first quarter, Agilent’s Cross Lab Group (ACG) segment is likely to have benefited from an increase in the service agreement connect rate.
The Zacks Consensus Estimate for ACG is pegged at $363 million, implying growth of 1.1% from the year-ago fiscal quarter’s reported figure.
Agilent’s Strength in NASD and Genomics portfolio is likely to have contributed well to the Diagnostics and Genomics Group (DGG) segment in its first quarter fiscal results.
The Zacks Consensus Estimate for DGG is pegged at $343 million, implying growth of 1.2% from the year-ago fiscal quarter’s reported figure.
Furthermore, strength in the Americas region and growth in the European and China businesses are expected to have remained tailwinds in the quarter under discussion.
However, uncertainties related to the coronavirus pandemic are expected to get reflected in the upcoming quarterly results.
Further, mounting expenses and macroeconomic headwinds are likely to have remained a concern in the quarter under review.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for A this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter
Agilent has an Earnings ESP of 0.00% and a Zacks Rank #2 at present.
Stocks to Consider
Here are some stocks that you may consider, as our model shows that they have the right combination of elements to beat on earnings this season.
CrowdStrike (CRWD - Free Report) has an Earnings ESP of +2.33% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
CrowdStrike is scheduled to release its fourth-quarter fiscal 2023 results on Mar 7. The Zacks Consensus Estimate for CRWD’s earnings is pegged at 43 cents per share, suggesting an increase of 43.3% from the prior-year quarter’s reported figure.
Axonics (AXNX - Free Report) has an Earnings ESP of +31.03% and a Zacks Rank #3 at present.
Axonics is set to report its fourth-quarter 2022 results on Mar 1. The Zacks Consensus Estimate for AXNX’s loss is pegged at 23 cents per share, narrower than the loss of 34 cents reported in the year-ago quarter.
Broadcom (AVGO - Free Report) ESP of +1.36% and a Zacks Rank #3 at present.
Broadcom is scheduled to release its first-quarter fiscal 2023 results on Mar 2. The Zacks Consensus Estimate for AVGO’s earnings is pegged at $10.16 per share, suggesting an increase of 21.1% from the prior-year period’s reported figure.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.